Apimeds Pharmaceuticals US (APUS) Research & Development (2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Research & Development came in at $361104.0 in Q4 2025, down 41.73% on a QoQ basis from $619693.0 in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Research & Development (2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 1 years of Research & Development data on file, last reported at $361104.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Apimeds Pharmaceuticals US | 7.52 Mn | 7.52 Mn | - | 959,742.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 361,104.00 |
| Sep 30, 2025 | 619,693.00 |
| Jun 30, 2025 | 651,784.00 |